Jianqing Lin, MD is an Associate Professor of Medicine at the GW School of Medicine & Health Sciences. Dr. Lin received his Medical Degree from Zhejiang Medical University, China in 1986. Dr. Lin was trained as a Research Fellow at the Boston Children’s Hospital, Harvard Medical School from 1997 to 2003. He completed his Internal Medicine Residency at Carney Hospital, Tufts University School of Medicine in 2006. Following his Residency, Dr. Lin completed clinical fellowship in Medical Oncology at Johns Hopkins University in 2009. He has particular expertise in the area of cancer immunotherapy and the latest systemic treatment for prostate, bladder, kidney and testicular cancer. He is board certified in Internal Medicine and Medical Oncology and is licensed in the state of Pennsylvania and the District of Columbia.
Primary objective to compare the overall survival (OS) in patients with metastatic RCC treated with ipilimumabnivolumab followed by either nivolumab versus cabozantinib-nivolumab.Secondary objectives: To determine PFS of patients treated with nivolumab versus nivolumab-cabozantinibTo evaluate…
Patients who have metastatic RCC who are not eligible for surgery will all receive initial doses of Nivolumab and Ipilimumab.
Primary objective: to determine DFS and OS in all patients with muscle-invasive bladder and upper-tract urothelial carcinoma treated with adjuvant MK-3475 (pembrolizumab) vs. observation.